BioCryst Pharmaceuticals (BCRX) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vir Biotechnology (VIR) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 83.8% versus a gain of 20.9%. Over five years, BCRX leads with a -44.5% price change compared with -70.5% for VIR. BioCryst Pharmaceuticals is the larger company by market cap ($2.12 billion vs $1.88 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | VIR |
|---|---|---|
| Share price | $8.29 | $11.12 |
| Market cap | $2.12B | $1.88B |
| 1-day change | -1.31% | -3.47% |
| YTD return | +7.69% | +84.41% |
| 1-year return | +20.86% | +83.80% |
| 5-year return | -44.48% | -70.53% |
| Forward P/E | 8.82 | — |
| EPS (TTM) | $-1.40 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.22 | $11.94 |
| 52-week low | $6.00 | $4.82 |
| Distance from 52-week high | -26.11% | -6.87% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +150.06% | +86.87% |
| Average volume | 4.11M | 1.90M |
| Shares outstanding | 255.54M | 169.22M |
| Employees | 435 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VIR has outperformed BCRX by 62.9 percentage points over the past year.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
BCRX vs VIR FAQ
Which is bigger, BioCryst Pharmaceuticals or Vir Biotechnology?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.12B compared with $1.88B for Vir Biotechnology (VIR).
Which stock has performed better over the past year, BCRX or VIR?
VIR returned +83.80% over the past 12 months, compared with +20.86% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.